Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

faldaprevir

Novartis day

Novartis claims first place for its biosimilar Enbrel in US

However, Amgen’s patent infringement lawsuit could delay the launch of Erelzi

Novartis day

Novartis drug works in secondary progressive MS

Orally-active siponimod reduces risk of disability progression

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

- PMLiVE

Portola rejection hands advantage to Boehringer’s Pradaxa

FDA’s ruling on reversal agent for NOACs unexpected

Novartis day

Novartis plans major expansion of French antibody facility

Project aims to boost capacity by 70% and create new jobs

Deal Watch July 2016

Real deals, real money and - for some - reality bites

- PMLiVE

Patient reporting rises after EU pharmacovigilance reforms

Safety issues detected more quickly with increased patient participation

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

- PMLiVE

Germany’s IQWIG ‘perplexed’ by EMA’s adaptive pathways plan

Reliance on real-world evidence questioned

Sanofi reception

EC approves Sanofi’s deal for Boehringer’s consumer business

Regulator passes the acquisition, subject to the French firm divesting some products

- PMLiVE

EMA says adaptive pathways programme still needs refinement

Scheme aims to accelerate patient access to new drugs

Novartis Gehry Building

NICE backs Cosentyx for ankylosing spondylitis

The immunotherapy is on course to be “one of the most successful launches in Novartis history”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links